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Background: Clinicians often prescribe antimicrobials for outpatient wound infections before culture results are
known. Local or national MRSA rates may be considered when prescribing antimicrobials. If clinicians prescribe in
response to national rather than local MRSA trends, prescribing may be improved by making local data accessible.
We aimed to assess the correlation between outpatient trends in antimicrobial prescribing and the prevalence of
MRSA wound infections across local and national levels.
Methods: Monthly MRSA positive wound culture counts were obtained from The Surveillance Network, a database
of antimicrobial susceptibilities from clinical laboratories across 278 zip codes from 1999–2007. Monthly outpatient
retail sales of linezolid, clindamycin, trimethoprim-sulfamethoxazole and cephalexin from 1999–2007 were obtained
from the IMS Health XponentTM database. Rates were created using census populations. The proportion of variance
in prescribing that could be explained by MRSA rates was assessed by the coefficient of determination (R2), using
population weighted linear regression.
Results: 107,215 MRSA positive wound cultures and 106,641,604 antimicrobial prescriptions were assessed.
The R2 was low when zip code-level antimicrobial prescription rates were compared to MRSA rates at all
levels. State-level prescriptions of clindamycin and linezolid were not correlated with state MRSA rates. The
variance in state-level prescribing of clindamycin and linezolid was correlated with national MRSA rates
(clindamycin R2 = 0.17, linezolid R2 = 0.22).
Conclusions: Clinicians may rely on national, not local MRSA data when prescribing clindamycin and
linezolid for wound infections. Providing local resistance data to prescribing clinicians may improve
antimicrobial prescribing and would be a possible target for future interventions.
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Methicillin-resistant Staphylococcus aureus (MRSA) is a
major cause of outpatient wound infections, especially in
the era of community-associated MRSA [1-10]. In the out-
patient setting, physicians often prescribe antimicrobials
for wound infections before culture results are known. The
Infectious Diseases Society of America (IDSA) and U.S.
Centers for Disease Control and Prevention recommend
empirical coverage aimed at community-associated MRSA
for outpatient wound infections if MRSA is common in that
community. This empiric coverage includes clindamycin,
trimethroprim-sulfamethoxazole, or linezolid [2-7]. The
CDC specifically recommends that healthcare facilities
know infection and resistance trends in their facility and
facilities nearby to fight the spread of resistance [5,6].
When prescribing empiric antibiotic therapy, clinicians
may be influenced by many factors including patient
symptoms, patient risk factors, and the prevalence of
MRSA nationally or in their community. This study aims
to assess whether variation in prescribing practice is
influenced by local, state or national prevalence of MRSA.
Antibiotic-resistance rates at the national level may not
correlate with local resistance rates under which antimi-
crobials are prescribed empirically. Local rates of MRSA
infections could help determine the probability that the
current patient is infected with MRSA. Yet, if these rates
are not known or difficult to access, clinicians may be
forced to rely solely on national MRSA trends.
Prior studies have found that local and national pre-
scribing of anti-MRSA antimicrobials increased after
the introduction of community-associated MRSA wound
infections [7-10]. However, those studies also found that
many patients received empiric therapy with antibiotics
that were inactive against locally circulating strains of
MRSA [7,8].
The present study compared outpatient trends in anti-
microbial prescribing and the extent of their correlation
with the prevalence of MRSA wound infections across local
(i.e. zip code, state), and national levels. If local prescribing
does not appear to be correlated with local rates of MRSA
infections, then this may identify an opportunity for future
intervention trials that assess the benefit of providing
clinicians with local antibiogram data.
Materials and Methods
Sources of data
Data from two different databases were compared. Data
on monthly outpatient prescriptions per zip code were
obtained for the period of January 1999 to December
2007 from the IMS Health XponentTM database. The
IMS Health XponentTM database tracks more than 70% of
all outpatient prescriptions in the United States using trans-
action records at retail pharmacies, and uses a patented
projection methodology to represent 100% coverage of allprescription activity. Monthly outpatient prescription
rates were calculated for clindamycin, linezolid, and
trimethoprim-sulfamethoxazole. We chose these antimicro-
bials because they are recommended for outpatient empiric
therapy for suspected MRSA wound infections [2,3].
Cephalexin, an antimicrobial to treat methicillin-susceptible
S. aureus infections, was assessed to determine whether
rates of cephalexin prescribing decreased when rates of
MRSA infections increased.
Data on monthly outpatient MRSA wound infections
per laboratory zip code for the period of January 1999 to
December 2007 were collected from The Surveillance
Network (TSN; Eurofins Medinet, Herndon, VA). TSN is
a nationally and regionally representative database of bac-
terial species identification and antimicrobial susceptibility
results gathered from 300 US hospitals among 278 zip
codes [11,12]. Participating laboratories are geographically
dispersed and constitute a nationally representative sample
based on hospital bed size and patient population. These
laboratories are required to submit all bacterial isolates to
TSN. Only laboratories that are certified by the Clinical
Laboratory Standards Institute (CLSI) and that report on
the basis of CLSI reference methods are included in TSN
[13]. Results were filtered to remove repeat isolates.
MRSA infection was defined as a S. aureus positive
culture resistant to oxacillin. Only outpatient MRSA wound
infections from the TSN database were included in this
study. These included surgical wounds, soft tissue in-
fections and infections associated with intravascular
devices and catheters. Data from the US Census 2000
were used to assess the population of each zip code in-
cluded in each study.
Statistical analysis
Monthly MRSA-positive wound culture rates were
compared to rates of antimicrobial prescribing at the
zip code, state and national levels. Zip code level rates
were calculated using the US census 2000 populations
for each zip code. The denominator for each state level
rate was the sum of the zip code populations included
in this study for each state. The denominator for the
national level rates was the sum of the US census 2000
populations for each of the 278 zip codes included in
this analysis. The proportion of variance in prescribing
that could be explained by MRSA rates was assessed by
the coefficient of determination (R2), using population
weighted linear regression [14].
The coefficient of partial determination was calculated
to measure the marginal effect of MRSA infection when
time was already accounted for in the model [14]. To cal-
culate the coefficient of partial determination, a full model
of the log-transformed rate of antimicrobial prescriptions
was first estimated when time, MRSA infection, and the
interaction of time with MRSA infection were considered
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rate of antimicrobial prescriptions with time only was
then estimated. The relative marginal reduction in the
variation of antimicrobial prescriptions between the two
models was calculated to measure the additional contri-
bution of MRSA infection to the antimicrobial prescrip-
tions. All analyses were performed using SAS software
(SAS Institute, Cary, NC) version 9.2.
Ethics
The funding source, Robert Wood Johnson Foundation,
had no role in study design; collection, analysis, and
interpretation of data; in the writing of the report; or the
decision to submit the paper for publication. This study
deemed to be not human subjects research and IRB ap-
proval was waived by the University of Iowa IRB. Patient
consent was also waived by the University of Iowa IRB as
the data were deidentified and previously collected.
Results
From January 1, 1999 to December 31, 2007 there were
13,295 prescriptions for clindamycin, 10,973 prescrip-
tions for linezolid, 8,307 prescriptions for trimethoprim-
sulfamethoxazole and 3,022 prescriptions for cephalexin in
the IMS Health XponentTM database. The national rates of
clindamycin and linezolid prescribing increased over time
(p < 0.01). The national rates of cephalexin prescribing
decreased over time (p < 0.01).
There were 107,215 MRSA positive wound cultures
in TSN database. The national rates of MRSA wound
infections increased from 23.9 MRSA infections per
million people in January 1, 1999 to 118.7 MRSA infec-
tions per million people in December 31, 2007 (p < 0.01).
Antimicrobial prescribing at the zip code level was not
correlated with zip code, state or national MRSA infection
rates (R2 < 0.10) for clindamycin, linezolid, trimethoprim-
sulfamethoxazole or cephalexin. The correlations between
zip code level prescribing and zip code level infection rates
are presented in Table 1.
State level prescriptions of trimethoprim-sulfamethoxazole
and cephalexin were not well described by state or nationalTable 1 Proportion of variance (r2) in zip code level antimicro
MRSA wound infection rates





aR2 represents the unadjusted proportion of variance in prescribing that could be e
bCoefficient of Partial Determination represents the marginal effect of MRSA infectio
Source: Author’s calculations with susceptibility information from The Surveillance N
January 1999-December 2007, IMS Health Incorporated. All Rights Reserved.rates of MRSA (R2 < 0.01). State level prescriptions of
clindamycin were not correlated with state level MRSA
rates (R2 < 0.01). State level prescriptions of linezolid were
also not correlated with state MRSA rates (R2 = 0.004).
The variance in state level prescribing of clindamycin
and linezolid was best explained by national MRSA rates
(clindamycin R2 = 0.17; linezolid R2 = 0.22) (Table 2).
Thus, the proportion of variance in state-level prescribing
of clindamycin that can be described by national MRSA
wound infection rates is 17% and the proportion of
variance of linezolid prescribing that can be described by
national MRSA wound infection rates is 22%. State level
prescribing for trimethoprim-sulfamethoxazole, cephalexin,
clindamycin and linezolid and national MRSA wound in-
fection rates are graphically represented in Figure 1.
The proportion of variance in cephalexin and
trimethoprim-sulfamethoxazole prescribing explained
by infection rates remained low in the coefficient of
partial determination models. For rates of linezolid pre-
scribing, the coefficient of partial determination model
that accounted for the interaction between time and
infection rates resulted in the same proportion of vari-
ance in prescribing explained by infection rates as the
unadjusted model (state level infection rate R2 = 0.004,
national level infection rate R2 = 0.22). However, the
proportion of variance in clindamycin prescribing described
by national MRSA infection rates decreased substantially
(R2 = 0.007) (Table 2).
Discussion
Over the nine-year study period, we found that state-level
clindamycin and linezolid rates are correlated with national
MRSA wound infection rates, but not correlated with zip
code or state level MRSA wound infection rates. These
results suggest that national, not local, MRSA data may be
influencing clinicians’ decisions when prescribing empiric
antimicrobials in the outpatient setting. This is at odds with
CDC recommendations that facilities keep track of local
rates of resistant infections in order to fight the spread of
MRSA [4-6]. Thus, efforts by hospitals or health depart-
ments to share state or local MRSA rates with cliniciansbial prescribing that could be explained by zip code level
infection rate (R2)a Zip code level infection rate





xplained by MRSA rates using population weighted linear regression;
n on prescribing when time was already accounted for in the model.
etwork® (TSN) and prescription data derived from IMS Health Xponent™
Table 2 Proportion of variance (R2) in state level antimicrobial prescribing that could be explained by MRSA wound















Trimethoprim-sulfamethoxazole <0.001 0.03 0.10 0.004
Cephalexin <0.001 0.01 0.08 0.003
Linezolid 0.004 0.22 0.004 0.22
Clindamycin <0.001 0.17 0.10 0.008
aR2 represents the unadjusted proportion of variance in prescribing that could be explained by MRSA rates using population weighted linear regression;
bCoefficient of Partial Determination represents the marginal effect of MRSA infection on prescribing when time was already accounted for in the model.
Source: Author’s calculations with susceptibility information from The Surveillance Network® (TSN) and prescription data derived from IMS Health Xponent™
January 1999-December 2007, IMS Health Incorporated. All Rights Reserved.
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prescribing and antimicrobial stewardship in general.
Local knowledge of MRSA infection and resistance
trends can improve outpatient antibiotic prescribing.
For example, a study by Marra et al., found that out-
patient clinicians increased their use of clindamycin
and trimethoprim-sulfamethoxazole after a regional
(Western Canada) epidemic of community-associated
MRSA. Yet the clinicians in that region also frequently
prescribed clindamycin even though the predominant
MRSA strain in that region was resistant to clindamycin
[7]. Similarly, Gupta et al. found that although local rates
of community-associated MRSA skin and soft tissue infec-
tions were increasing, the majority of patients with these in-
fections were still receiving inactive antimicrobial therapy
[8]. A good example of reporting MRSA rates at a regionalFigure 1 State Level Prescribing and National MRSA Rates. a. State-lev
linezolid prescribing vs. national MRSA rates. c. State-level cephalexin presc
sulfamethoxazole prescribing vs. national MRSA rates. Note: Box and whiske
of monthly antimicrobial prescribing among all states in the IMS Health Xp
Source: Author’s calculations with susceptibility information from The Surve
Xponent™ January 1999-December 2007, IMS Health Incorporated. All Righlevel is the European Antimicrobial Resistance Surveillance
System (EARSS) in which individual countries share their
MRSA rates [15]. If other regions such as U.S. states or
Canadian provinces similarly shared their MRSA rates,
local clinicians would be able to use those rates to enhance
antimicrobial prescribing.
This study found no correlation between zip code level
antimicrobial prescribing and rates of MRSA wound infec-
tions. This could be due to two factors. First, clinicians
may not have knowledge of zip code level rates of MRSA
wound infections. However, it is likely that the zip code
was too small of a unit of analysis. Zip code level rates of
antimicrobial prescribing and infection data varied greatly
from month to month. For instance, in one zip code the
MRSA infection rate varied from 6.0 MRSA infections per
10,000 people in one month to 2.7 per 10,000 people inel clindamycin prescribing vs. national MRSA rates. b. State-level
ribing vs. national MRSA rates. d. State-level trimethoprim/
r plots represent median, interquartile range and whisker boundaries
onentTM database; line represents monthly national MRSA rates.
illance Network® (TSN) and prescription data derived from IMS Health
ts Reserved.
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difficult to correlate with any other measure. The zip code
data are also limited because we assessed pharmacy zip
codes and laboratory zip codes but we did not have access
to the patients’ zip codes. It is possible that these zip codes
may not coincide with a patient’s own zip code.
Rates of trimethoprim-sulfamethoxazole prescribing
were not associated with MRSA wound infection rates
at the zip code, state and national level. This is most
likely because trimethoprim-sulfamethoxazole is pre-
scribed for a variety of pathogens in the outpatient set-
ting and is not as well correlated with MRSA infections
as linezolid or clindamycin, which are prescribed for a
fewer number of indications [16]. It is interesting to
note that when time was adjusted for in the statistical
models, the correlation between national MRSA infection
rates and linezolid prescribing remained, but the correlation
between national MRSA infection rates and clindamycin
prescribing decreased substantially. This demonstrates that
the correlation between MRSA infection rates and linezolid
prescribing is not solely due to increased use of linezolid
after linezolid was FDA approved. However, further re-
search is needed to determine why the correlation between
clindamycin prescribing and national MRSA outpatient
infection rates was influenced by time. Potential reasons
for changes in clindamycin prescriptions over time include
replacement of clindamycin by other antimicrobials, use of
clindamycin for infections other than MRSA, concern in
regards to the association between antimicrobial use and
Clostridium difficile infections, or improved antimicrobial
stewardship in the outpatient setting.
Our findings are consistent with those of other studies
and the recent CDC Active Bacterial Core findings that
community-onset MRSA rates remained steady over time,
even though rates of healthcare-onset MRSA have been
declining in recent years [7-10,17]. In fact, that CDC study
found that for the first time, community-onset MRSA
infection rates have surpassed healthcare-onset MRSA rates
[17]. Thus, it is more important than ever to provide out-
patient clinicians with the resources they need to prescribe
appropriate antibiotics in the outpatient setting.
This study is limited by its ecologic study design. Some
patients may have received MRSA-directed antimicrobial
therapy without having a culture sent to the laboratory,
thus they would be represented in the IMS Health
XponentTM database but not in TSN database. However,
the IDSA guidelines recommend that cultures be collected
and tested from abscesses and other purulent skin and
soft tissue infections in patients treated with antimicrobial
therapy [2,3]. Thus, patients should be included in both
databases. Additionally, MRSA infection was measured
by positive culture results rather than the more stringent
Centers for Disease Control and Prevention (CDC) National
Healthcare Safety Network (NHSN) criteria. However,a study by Harris et al., found that 82% of MRSA positive
clinical cultures were MRSA infections as defined by CDC
NHSN criteria [18]. Therefore, the majority of clinical cul-
tures in our dataset should be true MRSA infections, not
laboratory contaminants. Also, the laboratories included in
TSN were chosen to be nationally representative of hospi-
talized patient populations but may not be representative of
all patients receiving outpatient care for wound infections.
These laboratories may be located in more urban settings
in which MRSA is more likely to be suspected compared
with rural settings.
Although national rates of MRSA infections were statis-
tically significantly associated with state-level prescribing
of clindamycin or linezolid, the R2 values were not excep-
tionally high (22% and 17%), meaning that the majority
(78% to 83%) of variation in antimicrobial prescribing was
due to factors other than national rates of MRSA infec-
tion. Other factors that would contribute to variation in
antimicrobial prescribing include patient signs and symp-
toms, patient risk factors and severity of infection [2,3].
All of these factors should contribute to therapy decisions.
Clinician access to geographic variations in rates of MRSA
infections would be just one more tool to assist in the
determination of which empiric therapy to prescribe.
We performed this study in order to generate a hypoth-
esis as to whether clinicians rely on local or national MRSA
data when prescribing antimicrobials. Future studies should
survey clinicians in order to determine what factors are
considered when prescribing empirical antimicrobials for
suspected wound infections. In summary, clinicians may
be relying on national, not local data, when prescribing
antimicrobials for suspected wound infections. Local efforts
to disseminate local MRSA rates to clinicians may improve
empiric prescribing of antimicrobials and should be consid-
ered for study in future intervention trials.
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